Revelation Biosciences (REVB)

Executive Summary

Revelation Biosciences is a clinical-stage biotechnology company headquartered in San Diego, California, focused on developing novel immunomodulatory therapies that rebalance the inflammatory response to treat infectious and inflammatory diseases. Its lead asset, GEMINI, is a proprietary innate immune system modulator designed to address a wide range of inflammatory conditions. The company is publicly traded (NASDAQ: REVB) and has a current market capitalization of approximately $3.99 million. While still in early clinical stages and without any approved products, Revelation differentiates itself through its unique approach to immune system modulation, targeting both infectious and chronic inflammatory diseases. The company's prospects depend heavily on successful clinical trial outcomes, particularly for GEMINI, and its ability to advance additional pipeline candidates. Given the early-stage nature and inherent clinical risks, the investment thesis hinges on positive data readouts that could de-risk the platform and attract partnership opportunities.

Upcoming Catalysts (preview)

• 2026Phase 2 clinical data readout for GEMINI in an inflammatory indication40% success
• 2027IND filing or initiation of a new clinical trial for a second indication50% success
• 2026Potential partnership or licensing deal for GEMINI or platform25% success